New therapeutic options for the treatment of HCV infection are highly effective, possess minimal side effects, and allow for a shortened course of therapy, presenting a favorable scenario to treat and cure all patients chronically infected with HCV. However, there are still many challenges to advancement towards HCV eradication, not only related to the cost and the availability of the drugs, but also pertaining to epidemiologic, diagnostic, and treatment issues that remain to be resolved. Advances in the knowledge of all these topics are essential for the optimization of diagnostic and treatment strategies to fight again HCV infection. The latest data presented at the I Conference of the Group for the Study of Viral Hepatitis (GEHEP) (23-26 September, Spain) highlights relevant progress on many of these fronts for an overview of HCV infection at present. This review summarizes some of the major findings presented and discussed during the conference.